Aligos Therapeutics, Inc. (ALGS) stock
ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3010% below fair value
$2.16−0.41 (-15.95%)
Close on Nov 11, 2026Market cap $26.98MP/E –Yield –
Aligos Therapeutics statistics
67 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- Mar 4, 2027 (estimated, before the open)
- Last ex-dividend date
- No dividends
- Fundamentals through
- Sep 30, 2026
- Share price as of
- Nov 11, 2026
Valuation ratiosIndustry
- P/TBV Ratio
- 2.39
- 2.38
Enterprise valuationIndustry
- EV / Sales
- -0.71
- 2.65
Share statisticsIndustry
- Shares Change (YoY)
- 16.7%
- 10.9%
- Shares Change (QoQ)
- 0.19%
- 0.48%
- Shares Held by Institutions
- 18.4%
- 56.4%
Short sellingIndustry
- Short Interest
- 677,218
- –
- Short Interest Change
- -4.28%
- -0.80%
- Short % of Shares Outstanding
- 5.42%
- 6.30%
- Days to Cover
- 20.77
- 5.15
Stock price statisticsIndustry
- 52-Week High
- $13.69
- –
- 52-Week Low
- $2.02
- –
- 20-Day Moving Average
- $4.54
- –
- 50-Day Moving Average
- $5.11
- –
- 200-Day Moving Average
- $6.07
- –
- Average True Range (14)
- $0.54
- –
- Price Change (1 Week)
- -57.0%
- -0.58%
- Price Change (1 Month)
- -60.8%
- -0.28%
- Price Change (3 Months)
- -68.1%
- -17.1%
- Price Change (6 Months)
- -67.6%
- -20.1%
- Price Change (YTD)
- -76.8%
- -20.1%
- Price Change (1 Year)
- -68.6%
- -19.3%
- Price Change (3 Years)
- -85.6%
- -22.2%
- Price Change (5 Years)
- -99.5%
- -76.4%
- Average Volume (10 Days)
- 89,793
- –
- Average Volume (20 Days)
- 60,750
- –
- Average Volume (90 Days)
- 85,341
- –
- Relative Volume
- 3.11
- 0.73
- Relative Strength Index (14)
- 18.9
- 47.7
- Volatility (1 Year)
- 96.9%
- 80.2%
- Beta (5 Years)
- 1.50
- 1.08
MarginsIndustry
- Pretax Margin
- -1077.4%
- -11.8%
- EBITDA Margin
- -1244.2%
- -27.7%
Returns on capitalIndustry
- Return on Equity (ROE)
- -159.5%
- -51.3%
- Return on Assets (ROA)
- -84.5%
- -40.7%
- Return on Capital Employed (ROCE)
- -262.9%
- -38.1%
Financial positionIndustry
- Current Ratio
- 1.77
- 3.30
- Quick Ratio
- 1.59
- 2.40
GrowthIndustry
- Revenue Growth (YoY)
- 122.2%
- 7.26%
EfficiencyIndustry
- Asset Turnover
- 0.07
- 0.40
- Revenue Per Employee
- $71.09K
- $429.38K
- Profits Per Employee
- -$808.35K
- -$683.67K
- Employee Count
- 82
- 75
- WACC
- 12.4%
- 10.1%
Income statement (TTM)Industry
- Pretax Income
- -$62.80M
- -$13.23M
Balance sheetIndustry
- Net Cash (Debt)
- $31.09M
- $16.56M
- Net Cash Per Share
- $2.49
- $0.71
- Equity (Book Value)
- $11.31M
- $52.23M
- Book Value Per Share
- $0.91
- $1.50
- Tangible Book Value
- $11.31M
- $26.10M
- Working Capital
- $15.08M
- $78.41M
Cash flow (TTM)Industry
Dividends and yieldsIndustry
- Earnings Yield
- -245.7%
- -20.1%
Taxes and interestIndustry
- Income Tax
- $3.48M
- $74.00K
Scores and fair valueIndustry
- Altman Z-Score
- -24.54
- 0.31
- Piotroski F-Score
- 4
- 4
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ALGS | S&P 500 | Difference | ALGS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -59.6% | -2.4% | −57.1 pts | ||
| 3 months | -70.3% | -1.2% | −69.2 pts | ||
| Year to date | -76.8% | +12.3% | −89.1 pts | ||
| 1 year | -67.7% | +12.4% | −80.1 pts | ||
| 3 years | -87.6% | +78.8% | −166.4 pts | -50.2% | +21.4% |
| 5 years | -99.5% | +75.2% | −174.7 pts | -65.1% | +11.9% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
1M ALGS shares were sold short on Oct 30, 2026, down 4.3% from the previous report. At recent volumes it would take 20.8 days to buy them back. Over the last 20 sessions, 45.3% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 677,218 | -4.3% | 32,604 | 20.8 |
| Oct 15, 2026 | 707,471 | -0.2% | 32,549 | 21.7 |
| Sep 30, 2026 | 708,744 | +1.6% | 49,392 | 14.3 |
| Sep 15, 2026 | 697,683 | +7.6% | 45,449 | 15.3 |
| Aug 31, 2026 | 648,568 | +14.2% | 68,891 | 9.4 |
| Aug 14, 2026 | 568,056 | -6.3% | 209,382 | 2.7 |
| Jul 31, 2026 | 606,525 | +16.3% | 94,945 | 6.4 |
| Jul 15, 2026 | 521,416 | -4.0% | 514,195 | 1.0 |
| Jun 30, 2026 | 543,337 | -11.2% | 68,442 | 7.9 |
| Jun 15, 2026 | 611,712 | +6.0% | 99,837 | 6.1 |
| May 29, 2026 | 576,909 | +7.8% | 121,404 | 4.8 |
| May 15, 2026 | 535,177 | +9.3% | 155,219 | 3.5 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?